Symposium on early phase dose finding



Memorial Sloan Kettering Cancer CenterWeill Cornell Medical College Curriculum Vitae FORM(REQUIRED FORMAT)Version date:1/21/2021GENERAL INFORMATIONRequired Information:Name: First, Middle, LastAlexia E. IasonosOffice address:485 Lexington Ave, 2nd FloorNew York, NY. 10017Office telephone:646-888-8255Office fax:929-321-1516Work Email:Personal Email:iasonosa@Citizenship:USA and CypriotIf not a U.S. Citizen, do you have:Immigrant visa (green card)?Non-immigrant Visa?Type:Optional Information (not required but helpful): Birth place:Limassol, CyprusRace/Ethnicity:White/ GreekEDUCATIONAL BACKGROUNDAcademic Degree(s): B.A. and higher; institution name and location; dates attended; date of award. Expand the table as needed.Degree(abbreviation)Institution Name and LocationDates attendedYear AwardedB.S Mathematics & StatisticsUniversity of Cyprus, Cyprus09/1992-06/19961996M.S Biometry & StatisticsSUNY Albany, Albany, New York09/1996-05/19981998PhD Biometry & Statistics SUNY Albany, Albany, New York08/1999-05/20022002Post-doctoral training (include residency/fellowships): In chronological order beginning with post-doctoral training positions; include full titles, ranks and inclusive dates held. Expand the tables as needed.TitleInstitution name and locationDates held N/AContinuing Medical Education Courses/CertificatesCertificate or Course Institution Name and LocationDates attendedN/AOther Educational ExperiencesDescriptionInstitution Name and LocationDates attendedN/ALICENSURE, BOARD CERTIFICATION, MALPRACTICELicensure: Every physician appointed to the Hospital staff, except interns, and aliens in the US via non-immigrant visas, must have a New York State license or a temporary certificate in lieu of the license.a. StateNumberDate of issueDate of last registrationN/Ab. If no license:1. Do you have a temporary certificate?Yes/No/NAHave you passed the examination for foreign medical school graduates?Yes/No/NAc. DEA number (optional):N/Ad. NPI number (optional):N/ABoard CertificationFull Name of BoardCertificate #Dates of Certification (mm/dd/yyyy) – Start and End DatesN/AMalpractice InsuranceDo you have Malpractice Insurance?Yes / No / Anticipated / N/AName of Provider:Premiums paid by (choose one):SelfGroup (name):Institution (name):PROFESSIONAL POSITIONS AND EMPLOYMENTAcademic positions (teaching and research)TitleInstitution name and locationDates heldAssistant Member, Level 1Memorial Sloan Kettering Cancer Center, New York03/2005-04/2008Assistant MemberMemorial Sloan Kettering Cancer Center, New York04/2008-05/2013Associate Member, MHMemorial Sloan Kettering Cancer Center, New York05/2013-04/2019Member, MHMemorial Sloan Kettering Cancer Center, New York04/2019-presentHospital positions (e.g., attending physician)TitleInstitution name and locationDates heldAssistant Attending BiostatisticianMemorial Hospital for Cancer and Allied Diseases, New York03/2005-05/2013Associate Attending Biostatistician Memorial Hospital for Cancer and Allied Diseases, New York05/2013-04/2019Attending BiostatisticianMemorial Hospital for Cancer and Allied Diseases, New York04/2019-presentOther EmploymentTitleInstitution name and locationDates heldTeacher AssistantUniversity of Albany, Albany, NY09/1996-06/1997Research AssistantNY State Department of Health, Albany, New York09/1997-06/1998Senior StatisticianAC Nielsen, Nicosia, Cyprus08/1998-07/1999Teacher AssistantUniversity of Albany, Albany, New York08/1999-05/2000Research AssistantNY State Department of Health, Albany, New York05/2000-11/2000Research AssistantNY State Department of Labor, Albany, New York11/2000-08/2001Teacher AssistantUniversity at Albany, Albany, New York09/2001-07/2002Research BiostatisticianBristol Myers Squibb, Wallingford, CT08/2002-03/2005EMPLOYMENT STATUS (current or anticipated)Name of Employer(s): Memorial Sloan Kettering Cancer CenterEmployment Status (choose one, delete the others):Full-time salaried by Cornell-affiliated hospitalINSTITUTIONAL/HOSPITAL AFFILIATION1. Primary Hospital Affiliation:Memorial Hospital for Cancer and Allied Diseases2. Other Hospital Affiliations:N/A3. Other Institutional Affiliations:N/APERCENT EFFORT AND INSTITUTIONAL RESPONSIBILITIES CURRENT % EFFORT(%)Does the activity involve WCMC students/researchers? (Yes/No)TEACHING5%NoCLINICAL0%NoADMINISTRATIVE15%NoRESEARCH80%NoTOTAL100%INSTITUTIONAL RESPONSIBILITIESTeaching (e.g., specific teaching functions, courses taught, dates: For guidance refer to Teaching Metrics table. Report your teaching activities in the 4 areas of teaching shown below. To provide a more detailed teaching report, use the Teaching Activities Report template or Educator Portfolio template (strongly encouraged). Refer to it here as an attachment (e.g., see attached), and attach it to the CV.Didactic teaching: (e.g., lectures, continuing medical education courses, grand rounds, professional development programs, seminars, tutorials)MSKCC invited seminars presented:Continual Reassessment Method: simulations comparing four methods, Phase I Working GroupA review of Phase I designs in oncology: a comprehensive comparison of the Continual Reassessment Method with the standard 3+3 dose escalation scheme. Biostatistics Forum, Weill Cornell Medical CollegeImplementation of the continual reassessment method at MSKCC, Phase I Working GroupA comparison of the continual reassessment method with the standard up and down design, MSKCC Experimental Therapeutics Center RetreatEstimating the dose-toxicity curve from completed Phase I studies, Phase I Working GroupIntroduction to Biostatistics, Gynecologic Fellows Clinical trial design, Gynecology Service Conference Statistical analyses for retrospective reviews, Gynecology Service Conference, Fellows Didactic LectureClinical trial design, Radiation Oncology, Fellows LecturePhase I Clinical Trials, Quantitative Sciences Undergraduate Research StudentsHow to prepare a successful proposal for Young Investigator Awards?Reproducibility, replicability, rigor and transparency, Fellows LectureFellows lecture: How to prepare a successful proposal for YIAsReviewer and discussant for YIA and CDA applications (mock panel review)Clinical Trials: State of the Art lecture seriesPrecision Medicine lecture seriesReproducibility, replicability, rigor and transparency, Fellows LectureClinical Trials: State of the Art lecture seriesReviewer and discussant for YIA and CDA applications (mock panel review)K30 courseClinical Trials Design coursePediatrics service meeting on interim analysesEarly drug development scientific service meetingPhase I Clinical Trials, Quantitative Sciences Undergraduate Research StudentsReproducibility, replicability, rigor and transparency, Fellows LectureDates2007200720082009200920102014201420142018201820182019201920192019201920202020202020202020202020202020Mentorship: (e.g., mentor for medical student, graduate student, resident, clinical or postdoctoral research fellow or junior faculty projects; service as graduate student thesis advisor or committee member)Mentor: Kay See Tan, PhDMentor: Audrey Mauguen, PhDMentor: I-Hsin Lin, PhDDates04/2014 - present07/2017 - present12/2020 - presentClinical teaching: (e.g., teaching in the clinic or hospital including bedside teaching, teaching in the operating room, preceptor in clinic)N/ADatesAdministrative teaching leadership role: (e.g., residency or fellowship director,course or seminar director or co-director)Data and Safety Monitoring Committee for Phase I & II TrialsJunior Faculty CouncilResearch Council, Member Research Council, Co-chairDates03/2006-03/201210/2007-09/200903/2012-12/201812/2018-presentClinical care (duties, dates: To document clinical activities use the table below or, to document extensive clinical activities use the Clinical Portfolio template (strongly encouraged). Refer to it here as an attachment and attach it to the CV.Clinical Activity; Clinical Program DevelopmentDatesN/AResearch (duties, dates): Summarize research activities in the table below. Provide key contributions, and annotate key grants and publications or use a Statement of Key Contributions. Refer to it here and attach it to the CV.Research Activity / Key ContributionsDatesMy methodological research interest is in the design and analysis of clinical trials, with a focus in Phase I and Phase II adaptive designs. Through my collaborations with the Gynecological Oncology group I am exploring various biomarkers and assessing relationships to histology, distant metastasis and clinical outcome. I am heavily involved in vaccine trials with the focus in identifying valid endpoints for ovarian cancer patients, as part of the Ovarian Program Project. In addition, I am working with surgeons in building predictive models and nomograms in gynecologic cancers.Administrative Activities (duties, dates): Describe administrative activities in the table below. To document administrative activities more extensively use a supplemental statement, refer to it here and attach it to the CV.Administrative ActivityDatePhase I Working GroupDevelopmental Therapeutic CenterBiostatistics Faculty Search Committee, ChairBiostatistics Faculty Search CommitteeProtocol review and approval workshop01/2007-01/201301/2013-present08/2013-07/201402/2015-09/201702/2017-09/2017RESEARCH SUPPORTSummarize Past Research Support:“The Genomic and Immune Landscape Following Neoadjuvant Chemotherapy in Ovarian Cancer”Kaleidoscope of Hope FoundationAmount: $50,000Dates: 5/1/2016 - 4/30/2019PI: Alexandra Snyder CharenRole: Co-Investigator, 3%“Unmasking Ovarian Cancers to Induce Immune Control”Ovarian Cancer Research FundAmount: $136,364Dates: 2/1/2016 - 1/31/2019PI: Alexandra Snyder CharenRole: Co-Investigator, 5%“To Target WT1 tumor-associated antigen through T cell receptor-mimic monoclonal antibody in patients with recurrent ovarian cancer”Ovarian Cancer Research FundAmount: $267,844Dates: 1/1/2016-12/31/2018PI: David SpriggsRole: Co-Investigator, 5%“Designs for phase I trials of combinations of agents”R01 NIH# CA142859-04A1 Amount: $ 296,402Dates: 7/1/2011-4/30/2018PI: Mark Conaway Role: Subcontract PI, 10% effortExperimental Therapeutic Center, MSKCCAmount: $125,000Dates: 1/1/15-12/31/2015Role: Co-Investigator, 5% effort“Personalizing Phase I dose finding studies: taking into account individual patient risk”Translational and Integrative Medicine Research Fund (TIMRF)Amount: $65,000Dates: 4/1/2014-3/31/2015PI: Alexia IasonosRole: Principal Investigator, 20% effort“Early Clinical Trials of New anti-cancer agents with Phase I emphasis” U01 NIH # CA069856-16 Amount: $ 258,850Dates: 4/14/08-2/28/13PI: David SpriggsRole: Co-Investigator, 10% effort“Targeting the P13K pathway in women’s cancers”American Association of Cancer Research, SU2C-AACR-DT0209 (PI Sawyers)Amount: $950,000Dates: 11/1/09-10/31/14PI: Charles Sawyers Role: Co-Investigator, 25% effort“A Phase II Trial of Adjuvant WT1 Analog Peptide Vaccine in Patients with Recurrent Epithelial Ovarian Cancer who are in Second or Third Remission” MSKCC SocietyDates: 7/1/12-6/30/13PI: Roisin O'CearbhaillRole: Co-Investigator, 5% effort“Assessing the continual reassessment method as a phase I design by comparing it to the standard dose escalation scheme”Experimental Therapeutic Center at Memorial Sloan Kettering Cancer Center Amount: $50,000 (Year 1), $70,000 (Year 2)Dates: 7/1/07-7/1/09PI: Alexia Iasonos PhDRole: PI, 40% effortThe Byrne Foundation Amount: $320,000Dates: 1/1/06-12/31/07PI: George BoslRole: Co-Investigator, 20% effort“Novel Approaches to Ovarian Cancer Treatment”P20 OCRF-CA-01 Amount: $225,000Dates: 12/31/04-12/30/07PI: Carol AghajanianRole: Co-Investigator, 15% effort“Epithelial Ovarian Cancer Program Project” PO1 NIH # CA 52477-13A3Amount: $1,111,409Dates: 4/1/05-3/31/10PI: David SpriggsRole: Core Co-PI, 40% effortPO1 CA05826-38, NIH/ NCIAmount: $203,888Dates: 12/1/02 –11/30/05PI: George Bosl; Biostat Core PI: Colin BeggRole: Investigator, 10% effortFor Current extramural and intramural research funding, provide the following for each award: Source, amount, and duration of support (dates)Name of Principal InvestigatorIndividual's role in project, including percentage (%) effortCandidates are encouraged to annotate multi-investigator grants to clarify their role on the project (PI, Site PI, Project leader, Core director, etc.)Current Research Support (duplicate table as needed):Source“Epithelial Ovarian Cancer Program Project” PO1 NIH# CA190174Amount$862,654 ($79,025 for the Core)Duration9/1/2015-8/31/2021Principal InvestigatorPaul SabbatiniYour Role in ProjectCore PI% Effort20%Source“A Phase I Dose Escalation Study of ESK1Bispecific Tcell Engager (BiTE) Antibody Targeting WT1 for the Treatment of Patients with Recurrent Ovarian Cancers”GC242097 Center for Experimental Therapeutics Amount$ 300,000Duration1/1/2020 3/31/2021Principal InvestigatorChrisann Kyi Your Role in ProjectBiostatistician % Effort5%SourceCancer Center Support Grant”P30 NIH# CA008748Amount$545,058Duration1/20/2018-12/31/2023Principal InvestigatorCraig Thompson/Mithat Gonen Your Role in ProjectCo-Investigator% Effort5%Source“Novel approaches to locoregional and systemic immunotherapy for ovarian cancer” Congressionally Directed Medical Research Programs: W81XWH-16-1-0298Amount$141,693Duration9/30/2016 – 9/29/2021Principal InvestigatorDmitriy ZamarinYour Role in ProjectCo-Investigator% Effort5%SourceExperimental Drug Development Service Support, MSKCC/Bayer Corp. Amount$44,862Duration1/1/2020 – no end datePrincipal InvestigatorAlexander DrilonYour Role in ProjectCo-Investigator% Effort15%SourceSurgery Research and Development Fund, MSKCCAmount$273,023Duration1/1/15 – no end datePrincipal InvestigatorJeffrey Drebin/Nadeem Abu-RustumYour Role in ProjectCo-Investigator% Effort25%EXTRAMURAL PROFESSIONAL RESPONSIBILITIESi.e. - Journal Reviewer, Editorial Boards, Study Sections, Invited PresentationsActivity / Responsibility DatesInternational Activities:International Workshop in the Statistical Design of Phase I Studies, Organizer & ChairSymposium on early phase dose finding methodology, Scientific and Organizing Committee20092014-2015National & Regional Activities:American Statistical Association, Education Committee Chair, Connecticut ChapterAmerican Statistical Association, Treasurer (elected), Connecticut ChapterSociety for Clinical Trials Meeting, poster presenterNCI Gynecologic Cancer Steering Committee, Elected memberSusan G. Komen for the Cure, Scientific ReviewerCaucus for Women in Statistics, Representative (elected)ASCO Program Committee, Biostatistics Track, ReviewerInternational Society of Clinical Biostatistics, Membership CommitteeConquer Cancer Foundation of ASCO Grants Selection Committee, MemberSociety of Clinical Trials, Preconference Workshop InstructorInternational Society of Clinical Biostatistics, Preconference Workshop InstructorNCI, Working group of evaluating dose expansion cohortsNCI Ovarian Task Force, Elected MemberRoche, Scientific ForumENAR, Preconference Workshop InstructorAACR, Chairperson of the Biostatistics in Clinical Trials SectionJoint Statistical Meeting, Preconference Workshop InstructorSociety for Clinical Trials Meeting, Preconference Workshop InstructorSociety for Clinical Trials Meeting, Roundtable DiscussantSociety for Clinical Trials Meeting, Preconference Workshop InstructorSociety of Clinical Trials, Elected Board of Directors MemberInternational Society of clinical Biostatistics Meeting, Preconference Workshop InstructorNominating committee, Society of Clinical Trials, MemberConflict of Interest Task force, Society of Clinical Trials, ChairConquer Cancer, the ASCO Foundation Grant Selection Committee, reviewer2003-20052004-200520102008-20112008-20092009-20122012-present2012-2017201320132014-20152014-2017201520152016201620182018 – present 201920192019 - present2020202020202020Editorial Responsibilities:Ad hoc Reviewer for Journal of the National Cancer Institute; Journal of Clinical Oncology; Clinical Cancer Research; International Journal of Gynecological Cancer; Clinical Trials; Controlled Clinical Trials; Statistics in Medicine; BiometricsGuest Editor, Stats Med, Special Issue in Papers from the Workshop on Early Phase Dose Finding MethodologyAssociate Editor, Stats Med, Special Issue in Statistics in Medicine: Proceedings from ISCB meetingEditorial board, Member, Journal of Clinical OncologyAssociate Editor, Clinical TrialsGuest Editor Stats Med, Special Issue: Papers from the Symposium on Early Phase Dose Finding MethodologyAssociate Editor, Journal of Clinical OncologyCo-Editor Handbook of Methods for Designing, Monitoring, and Analyzing Dose Finding Trials; CRC Press, Taylor and Francis, Florida2007-present201020122014-present2015-present20162017-present2017Invited Seminars Presented:Albany Chapter American Statistical Association Meeting, NYAlbany Chapter American Statistical Association Meeting, NYWeill Cornell Medical College, Biostatistics Seminar, NYUniversity of Pennsylvania, Biostatistics Seminar, Philadelphia, PABaruch College, City University of New York, Biostatistics Seminar, New York, NY,University of Reading, Workshop on dose-finding methodology in early phase clinical trials, UKUniversity of California San Francisco, Biostatistics Seminar, CAUniversité Paris 6, Second workshop on dose-finding methodology in early phase clinical trials, FranceCancer Institute of New Jersey, University of Medicine and Dentistry of New Jersey, NJThe University of Texas MD Anderson Texas Cancer Center, TXJoint Statistical Meeting, San Diego, CAUniversity of Virginia, Charlottesville, VA Yale University, New Haven, CTMount Sinai Hospital, New York, NYJoint Statistical Meeting, Montreal, CanadaThird workshop on dose-finding methodology in early phase clinical trials, Ann Arbor, MichiganSymposium on early phase dose finding methodology, Paris, FranceThe Fifth International Workshop in Sequential Methodologies, New York, NYEastern North American Region, International Biometric Society, Miami, FLAmerican Association for Cancer Research Meeting, New Orleans, LAJoint Statistical Meeting, Chicago, ILInternational Chinese Statistical Association, Atlanta, GASociety for Clinical Trials Meeting, Montreal, Quebec, CanadaSymposium on Pharmacogenetic Epidemiology, New York, NYSymposium on early phase dose finding methodology, University of Virginia, VA14-International Conference on Malignant Lymphoma Workshop, Lugano, SwitzerlandJoint Statistical Meeting, Baltimore, MDJournal of Clinical Oncology, Editors’ Meeting, Washington DC, MDAlbert Einstein College of Medicine, NY, NYJoint Statistical Meeting, Vancouver, CanadaMount Sinai, Icahn School of Medicine, New York, NYUniversity of Minnesota, Minneapolis, MTWorkshop in Basket and Umbrella Trials for Oncology, PhiladelphiaBaruch College, CUNY, New York, NYSt. Jude’s Children’s Hospital, Memphis, TNJoint Statistical Meeting, roundtable discussant (Virtual)Join Statistical Meeting, invited speaker (Virtual)International Society of clinical Biostatistics, preconference workshop (Virtual)20012002200720092009201020112011201120122012201220122013201320132015201520152016201620162016201620172017201720172018201820182018201820182020202020202020PROFESSIONAL MEMBERSHIPSInclude medical and scientific societies.Member/Officer/Fellow/RoleOrganizationDatesMemberAmerican Statistical Association2001-2007; 2012-presentMemberAmerican Society of Clinical Oncology (ASCO)2006-presentMemberSociety of Clinical Trials2009-presentMemberInternational Society of Clinical Biostatistics2011-presentHONORS AND AWARDSName of awardDate awardedBest Presentation Award, Albany Chapter American Statistical Association (ASA) Conference2001Best Paper Award, Albany Chapter ASA Conference2001Pharmaceutical Research Institute Star Award, Bristol Myers Squibb2003Awarded competitive admission to the Association of American Medical Colleges (AAMC) Mid-Career Women Faculty Professional Development Seminar in Austin, TX2015BIBLIOGRAPHYEntries should follow standard journal format, listing all authors, complete titles and inclusive pagination. Please also provide a URL to each of your published works as found in a publicly available digital database such as PubMed or My Bibliography, which are maintained by the US National Library of Medicine.Publications also may be annotated here (or in the Key Contributions Statement) to indicate the role of the candidate, where appropriate. This should be considered for co-first authorship, co-senior authorship, and in publications in which the candidate played an important role (leadership of a site, or methodology, etc.) that may not be apparent from the author order.Number the entries and put your name in bold type. The listings must be organized in chronological order. Use the following categories:Articles in professional peer-reviewed journals1. Raj GV, Iasonos A, Herr H, Donat MS, Formulas Calculating Creatinine Clearance AreInadequate For Determining Eligibility For Cisplatin-Based Chemotherapy In Bladder Cancer. J Clin Oncol 2006; 24:3095-100.2. Abu-Rustum N, Alektiar K, Iasonos A, Lev G, Sonoda Y, Aghajanian C, Chi DS, Barakat RR. The Incidence of Symptomatic Lower-Extremity Lymphedema Following Treatment of Uterine Corpus Malignancies: An 11-Year Experience at Memorial Sloan-Kettering Cancer Center. Gynecol Oncol 2006;103(2):714-8.3. Sabbatini P, Dupont J, Aghajanian C, Derosa F, Poynor E, Anderson S, Hensley M, Livingston P, Iasonos A, Spriggs D, McGuire W, Reinartz S, Schneider S, Grande C, Lele S, Rodabaugh K, Kepner J, Ferrone S, Odunsi K. Phase I Study of the Anti-Idiotype Monoclonal Antibody Abagovomab in Patients with Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer. Clin Cancer Res 2006; 12:5503-10.4. Juretzka MM, Barakat RR, Chi DS, Iasonos A, et al. CA125 Level as a Predictor of Progression Free Survival and Overall Survival in Ovarian Cancer Patients with Surgically Defined Disease Status at the End of Primary Therapy. Gynecol Oncol 2007; 104:176-80.5. Raj GV, Bach AM, Iasonos A, Korets R, Blitstein J, Hann L, Russo P Predictng the histology of renal masses using pre-operative doppler ultrasonography. Journal of Urology 2007; 177:53-8. 6. Diefenbach CSM., Soslow RA, Iasonos A, Hedvat C, Bonham L, Singer J, Barakat R., Aghajanian C., Dupont J. Lysophosphatidic Acid Transferase-Beta (LPAAT-β) is Highly Expressed in Advanced Ovarian Cancer and is Associated with Aggressive Histology, Distant Metastases and Poor Survival. Cancer 2006; 107:1511-9.7. Diefenbach CSM, Shah Z, Iasonos A, Barakat RR et al. Pre-operative serum YKL-40 is a serum marker for detection and prognosis of endometrial cancer. Gynecol Oncol 2007; 104:435-42.8. Sabbatini P, Mooney D, Iasonos A, Thaler H, Aghajanian C, Hensley M, Tew W, Konner J, Spriggs D, Abu-Rustum N, Dupont J.CA-125 Patterns in Recurrent Ovarian Cancer treated with Carboplatin, Liposomal Doxorubicin, or Topotecan. Int J Gynecol Cancer 2007; 17:589-94.9. Basch E, Iasonos A; McDonough T, Barz A; Culkin A RN; Kris M; Scher HI, Schrag D.Patient versus clinician symptom reporting using the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE). The Lancet Oncology 2006; 7:903-9.10.Galsky MD, Iasonos A, Mironov S, Scattergood J, Boyle MG, Bajorin DF. Phase II trial of dose-dense doxorubicin plus gemcitabine followed by paclitaxel plus carboplatin in patients with advanced urothelial carcinoma and impaired renal function. Cancer 2007; 109:549-55.11.Galsky MD, Mironov S, Iasonos A, Scattergood J, Boyle MG, Bajorin DF.Phase II trial of pemetrexed as second-line therapy in patients with metastatic urothelial carcinoma. Invest New Drugs 2007; 25:265-70.12.Basch E, Artz D, Speakman J, Iasonos A, Shannon K, Lin K, Pun C, Yong H, Fearn P, Barz A, Scher HI, McCabe M, Schrag D.Evaluation of an online platform for cancer patient self-reporting of chemotherapy toxicities. J Am Med Inform Assoc 2007; 14:264-8.13.Dos Santos L, Mok E, Iasonos A, Park K, Soslow RA, Aghajanian C, Alektiar K, Barakat RR, Abu-Rustum NR. Squamous cell carcinoma arising in mature cystic teratoma of the ovary: A case series and review of the literature. Gynecol Oncol 2007; 105:321-4.14.Sabbatini P, Ragupathi G, Hood C, Aghajanian C, Juretzka M, Iasonos A, Hensley M, Spriggs D, Tew W, Konner J, Clausen H, Rustum NA, Dansihefsky S, Livingston P. Pilot study of a heptavalent vaccine-KLH conjugate plus QS21 in patients with epithelial ovarian, fallopian tube, or peritoneal cancer. Clin Cancer Res 2007; 13:4170-7.15.Galsky MD, Iasonos A, Mironov S, Scattergood J, Donat SM, Bochner BH, Herr HW, Russo P, Boyle MG, Bajorin DF.Prospective trial of ifosfamide, paclitaxel, and cisplatin in patients with advanced non-transitional cell carcinoma of the urothelial tract.Urology 2007; 69:255-9.16.Harrison ML, Gore ME, Spriggs D, Kaye S, Iasonos A, Hensley M, Aghajanian C, Venkatraman E, Sabbatini P. Duration of second or greater complete clinical remission in ovarian cancer: Exploring potential endpoints for clinical trials. Gynecol Oncol 2007; 106:469-75.17. Black D, Iasonos A, Ahmed H, Chi DS, Barakat RR, Abu-Rustum NR. Effect of perioperative venous thromboembolism on survival in ovarian, primary peritoneal, and fallopian tube cancer.Gynecol Oncol 2007; 107:66-70.Levine D, Park K, Juretzka M, Esch J, Hensley M, Aghajanian C, Lewin S, Konner J, Derosa F, Spriggs D, Iasonos A, Sabbatini P. A phase II evaluation of goserelin and bicalutamide in patients with ovarian cancer in second or higher complete clinical disease remission. Cancer 2007; 110:2458-66.Basch E, Iasonos A, Barz A, Culkin A, Kris MG, Artz D, Fearn P, Speakman J, Farquhar R, Scher HI, McCabe M, Schrag D. Long-term toxicity monitoring via electronic patient-reported outcomes in patients receiving chemotherapy. J Clin Oncol 2007 Dec 1;25(34):5374-80.Juretzka M, Hensley ML, Tew W, Konner J, Aghajanian C, Leitao M, Iasonos A, Soslow R, Park K, Sabbatini P. A phase 2 trial of oral imatinib in patients with epithelial ovarian, fallopian tube, or peritoneal carcinoma in second or greater remission. Eur J Gynaecol Oncol. 2008;29(6):568-72.Iasonos A, Wilton AS, Riedel ER, Seshan VE, Spriggs DR. A comprehensive comparison of the continual reassessment method to the standard 3 + 3 dose escalation scheme in Phase I dose-finding studies. Clin Trials 2008;5(5):465-77. PMCID: PMC2637378.Zivanovic O, Eisenhauer EL, Zhou Q, Iasonos A, Sabbatini P, Sonoda Y, Abu-Rustum NR, Barakat RR, Chi DS. The impact of bulky upper abdominal disease cephalad to the greater omentum on surgical outcome for stage IIIC epithelial ovarian, fallopian tube, and primary peritoneal cancer. Gynecol Oncol. 2008;108(2):287-92. Caceres A, Zhou Q, Iasonos A, Gerdes H, Chi DS, Barakat RR. Colorectal stents for palliation of large-bowel obstructions in recurrent gynecologic cancer: an updated series. Gynecol Oncol. 2008 Mar;108(3):482-5. Iasonos A, Schrag D, Raj GV, Panageas KS. How to build and interpret a nomogram for cancer prognosis. J Clin Oncol. 2008;26(8):1364-70. Review.Black D, Levine DA, Nicoll L, Chou JF, Iasonos A, Brown CL, Sonoda Y, Chi DS, Leitao MM, Abu-Rustum NR, Ferguson SE, Barakat RR. Low risk of complications associated with the fenestrated peritoneal catheter used for intraperitoneal chemotherapy in ovarian cancer. Gynecol Oncol. 2008;109(1):39-42. Abu-Rustum NR, Iasonos A, Zhou Q, Oke E, Soslow RA, Alektiar KM, Chi DS, Barakat RR. Is there a therapeutic impact to regional lymphadenectomy in the surgical treatment of endometrial carcinoma? Am J Obstet Gynecol. 2008;198(4):457.e1-5; discussion 457.e5-6.Diefenbach CS, Gnjatic S, Sabbatini P, Aghajanian C, Hensley ML, Spriggs DR, Iasonos A, Lee H, Dupont B, Pezzulli S, Jungbluth AA, Old LJ, Dupont J. Safety and immunogenicity study of NY-ESO-1b peptide and montanide ISA-51 vaccination of patients with epithelial ovarian cancer in high-risk first remission. Clin Cancer Res. 2008;14(9):2740-8.Thompson RH, Ordonez MA, Iasonos A, Secin FP, Guillonneau B, Russo P, Touijer K. Renal cell carcinoma in young and old patients--is there a difference? J Urol. 2008;180(4):1262-6; discussion 1266. PMCID: PMC2615196.Makker V, Abu-Rustum NR, Alektiar KM, Aghajanian CA, Zhou Q, Iasonos A, Hensley ML. A retrospective assessment of outcomes of chemotherapy-based versus radiation-only adjuvant treatment for completely resected stage I-IV uterine carcinosarcoma. Gynecol Oncol. 2008;111(2):249-54. Zivanovic O, Alektiar KM, Sonoda Y, Zhou Q, Iasonos A, Tew WP, Diaz JP, Chi DS, Barakat RR, Abu-Rustum NR. Treatment patterns of FIGO Stage IB2 cervical cancer: a single-institution experience of radical hysterectomy with individualized postoperative therapy and definitive radiation therapy. Gynecol Oncol. 2008;111(2):265-70. Zivanovic O, Leitao MM, Iasonos A, Jacks LM, Zhou Q, Abu-Rustum NR, Soslow RA, Juretzka MM, Chi DS, Barakat RR, Brennan MF, Hensley ML. Stage-specific outcomes of patients with uterine leiomyosarcoma: a comparison of the international Federation of gynecology and obstetrics and american joint committee on cancer staging systems. J Clin Oncol. 2009;27(12):2066-72.Milowsky MI, Nanus DM, Maluf FC, Mironov S, Shi W, Iasonos A, Riches J, Regazzi A, Bajorin DF. Final results of sequential doxorubicin plus gemcitabine and ifosfamide, paclitaxel, and cisplatin chemotherapy in patients with metastatic or locally advanced transitional cell carcinoma of the urothelium. J Clin Oncol. 2009;27(25):4062-7.Zivanovic O, Sima CS, Iasonos A, Bell-McGuinn KM, Sabbatini PJ, Leitao MM, Levine DA, Gardner GJ, Barakat RR, Chi DS. Exploratory analysis of serum CA-125 response to surgery and the risk of relapse in patients with FIGO stage IIIC ovarian cancer. Gynecol Oncol. 2009;115(2):209-14. Gallagher DJ, Milowsky MI, Iasonos A, Maluf FC, Russo P, Dalbagni G, Donat MS, Boyle MG, Zheng J, Riches J, Bajorin DF. Sequential adjuvant chemotherapy after surgical resection of high-risk urothelial carcinoma. Cancer. 2009;115(22):5193-201.O'Cearbhaill R, Zhou Q, Iasonos A, Soslow RA, Leitao MM, Aghajanian C, Hensley ML. Treatment of advanced uterine leiomyosarcoma with aromatase inhibitors. Gynecol Oncol. 2010;116(3):424-9.O'Cearbhaill R, Zhou Q, Iasonos A, Hensley ML, Tew WP, Aghajanian C, Spriggs DR, Lichtman SM, Sabbatini PJ. The prophylactic conversion to an extended infusion schedule and use of premedication to prevent hypersensitivity reactions in ovarian cancer patients during carboplatin retreatment. Gynecol Oncol. 2010;116(3):326-31.Garg K, Shih K, Barakat R, Zhou Q, Iasonos A, Soslow RA. Endometrial carcinomas in women aged 40 years and younger: tumors associated with loss of DNA mismatch repair proteins comprise a distinct clinicopathologic subset. Am J Surg Pathol. 2009;33(12):1869-77.Basch E, Jia X, Heller G, Barz A, Sit L, Fruscione M, Appawu M, Iasonos A, Atkinson T, Goldfarb S, Culkin A, Kris MG, Schrag D. Adverse symptom event reporting by patients vs clinicians: relationships with clinical outcomes. J Natl Cancer Inst. 2009;101(23):1624-32. PMCID: PMC2786917.Sabbatini P, Spriggs D, Aghajanian C, Hensley M, Tew W, Konner J, Bell-McGuinn K, Juretzka M, Iasonos A. Consolidation strategies in ovarian cancer: observations for future clinical trials. Gynecol Oncol. 2010;116(1):66-71.Abu-Rustum NR, Zhou Q, Gomez JD, Alektiar KM, Hensley ML, Soslow RA, Levine DA, Chi DS, Barakat RR, Iasonos A. A nomogram for predicting overall survival of women with endometrial cancer following primary therapy: toward improving individualized cancer care. Gynecol Oncol. 2010;116(3):399-403.Carter J, Sonoda Y, Baser RE, Raviv L, Chi DS, Barakat RR, Iasonos A, Brown CL, Abu-Rustum NR. A 2-year prospective study assessing the emotional, sexual,and quality of life concerns of women undergoing radical trachelectomy versusradical hysterectomy for treatment of early-stage cervical cancer. Gynecol Oncol. 2010;119(2):358-65. PubMed PMID: 20817227. Shih KK, Zhou QC, Aghajanian C, Huh J, Soslow RA, Morgan JC, Iasonos A, Chi DS, Barakat RR, Abu-Rustum NR. Patterns of recurrence and role of adjuvant chemotherapy in stage II-IV serous ovarian borderline tumors. Gynecol Oncol. 2010;119(2):270-3. PubMed PMID: 20719369.Fu M, Maresh EL, Soslow RA, Alavi M, Mah V, Zhou Q, Iasonos A, Goodglick L, Gordon LK, Braun J, Wadehra M. Epithelial membrane protein-2 is a novel therapeutic target in ovarian cancer. Clin Cancer Res. 2010;16(15):3954-63. PubMed PMID: 20670949; PubMed Central PMCID: PMC2913478.Dharma Rao T, Park KJ, Smith-Jones P, Iasonos A, Linkov I, Soslow RA, Spriggs DR. Novel monoclonal antibodies against the proximal (carboxy-terminal) portions of MUC16. Appl Immunohistochem Mol Morphol. 2010;18(5):462-72. PubMed PMID: 20453816.Moskowitz CH, Sch?der H, Teruya-Feldstein J, Sima C, Iasonos A, Portlock CS, Straus D, Noy A, Palomba ML, O'Connor OA, Horwitz S, Weaver SA, Meikle JL, Filippa DA, Caravelli JF, Hamlin PA, Zelenetz AD. Risk-adapted dose-dense immunochemotherapy determined by interim FDG-PET in Advanced-stage diffuse large B-Cell lymphoma. J Clin Oncol. 2010;28(11):1896-903. PubMed PMID: 20212248.Carter J, Raviv L, Appollo K, Baser RE, Iasonos A, Barakat RR. A pilot study using the Gynecologic Cancer Lymphedema Questionnaire (GCLQ) as a clinical care tool to identify lower extremity lymphedema in gynecologic cancer survivors. Gynecol Oncol. 2010;117(2):317-23. PubMed PMID: 20163847.Zivanovic O, Sima CS, Iasonos A, Hoskins WJ, Pingle PR, Leitao MM Jr, SonodaY, Abu-Rustum NR, Barakat RR, Chi DS. The effect of primary cytoreduction on outcomes of patients with FIGO stage IIIC ovarian cancer stratified by the initial tumor burden in the upper abdomen cephalad to the greater omentum. Gynecol Oncol. 2010;116(3):351-7. PubMed PMID: 20022092.Shih KK, Zhou Q, Huh J, Morgan JC, Iasonos A, Aghajanian C, Chi DS, Barakat RR, Abu-Rustum NR. Risk factors for recurrence of ovarian borderline tumors. Gynecol Oncol. 2011;120(3):480-4. PubMed PMID: 21146201. Iasonos A., Ostrovnaya I. Estimating the dose-toxicity curve in completed phase I studies. Statistics in Medicine 2011;30(17):2117-29.Gerecitano J, Portlock C, Hamlin P, Moskowitz CH, Noy A, Straus D, Schulman P, Dumitrescu O, Sarasohn D, Pappanicholaou J, Iasonos A, Zhang Z, Mo Q, Horanlli E, Rojas CN, Zelenetz AD, O'Connor OA. Phase I trial of weekly and twice-weekly bortezomib with rituximab, cyclophosphamide, and prednisone in relapsed or refractory non-Hodgkin lymphoma. Clin Cancer Res. 2011;17(8):2493-501. Abu-Rustum NR, Zhou Q, Iasonos A, Alektiar KM, Leitao MM Jr, Chi DS, Sonoda Y, Soslow R, Hensley M, Barakat RR. The revised 2009 FIGO staging system for endometrial cancer: should the 1988 FIGO stages IA and IB be altered? Int J Gynecol Cancer. 2011;21(3):511-6.Zivanovic O, Jacks LM, Iasonos A, Leitao MM Jr, Soslow RA, Veras E, Chi DS, Abu-Rustum NR, Barakat RR, Brennan MF, Hensley ML. A nomogram to predict postresection 5-year overall survival for patients with uterine leiomyosarcoma. Cancer 2012;118(3):660-9.Iasonos A, Zohar S, O'Quigley J. Incorporating lower grade toxicity information into dose finding designs. Clin Trials 2011;8(4):370-9.Hyman DM, Zhou Q, Arnold AG, Grisham RN, Iasonos A, Kauff ND, Spriggs D. Topotecan in patients with BRCA-associated and sporadic platinum-resistant ovarian, fallopian tube, and primary peritoneal cancers. Gynecol Oncol. 2011;123(2):196-9.Hensley ML, Kravetz S, Jia X, Iasonos A, Tew W, Pereira L, Sabbatini P, Whalen C, Aghajanian CA, Zarwan C, Berlin S. Eribulin mesylate (halichondrin B analog E7389) in platinum-resistant and platinum-sensitive ovarian cancer: A 2-cohort, phase 2 study. Cancer 2012;118(9):2403-10.Iasonos A, Sabbatini P, Spriggs DR, Aghajanian CA, O'Cearbhaill RE, Hensley ML, Thaler HT. Identifying clinical improvement in consolidation single-arm phase II trials in patients with ovarian cancer in second or greater clinical remission. Int J Gynecol Cancer 2012;22(1):63-9.Konner JA, Grabon DM, Gerst SR, Iasonos A, Thaler H, Pezzulli SD, Sabbatini PJ, Bell-McGuinn KM, Tew WP, Hensley ML, Spriggs DR, Aghajanian CA. A Phase II study of intraperitoneal paclitaxel plus cisplatin and intravenous paclitaxel plus bevacizumab as adjuvant treatment of optimal Stage II/III epithelial ovarian cancer. J Clin Oncol. 2011;29(35):4662-8.Hyman D, Zhou Q, Iasonos A, Grisham R, Arnold AG, Phillips MF, Bhatia J, Levine D, Aghajanian C, Barakta RR, Spriggs DR, Kauff ND. Improved survival for BRCA2-associated serous ovarian cancer compared with both BRCA-negative and BRCA1-associated serous ovarian cancer. Cancer 2012;118(15):3703-9.Polterauer S, Zhou Q, Grimm C, Seebacher V, Reinthaller A, Hofstetter G, Concin N, Leitao MM, Barakat RR, Abu-Rustum NR, Iasonos A. External validation of a nomogram predicting overall survival of patients diagnosed with endometrial cancer. Gyn Oncology 2012;125(3):526-30. Tanner EJ, Long KC, Zhou Q, Brightwell RM, Gardner GJ, Abu-Rustum NR, Leitao MM Jr, Sonoda Y, Barakat RR, Iasonos A, Chi DS. Impact of operative start time on surgical outcomes in patients undergoing primary cytoreduction for advanced ovarian cancer. Gynecol Oncol. 2012;125(3):526-30.Grisham RN, Adaniel C, Hyman DM, Ma W, Iasonos A, Aghajanian C, Konner J. Gemcitabine for advanced endometrial cancer: a retrospective study of the Memorial sloan-Kettering Cancer Center experience. Int J Gynecol Cancer. 2012;22(5):807-11.Iasonos A., O’Quigley J. Interplay of priors and skeletons in two-stage continual reassessment method. Statistics in Medicine 2012;31(30):4321-36. Iasonos A, Mrinal Gounder M, Spriggs DR, Gerecitano JF, Hyman DM, Zohar S, O’Quigley J. The impact of non–drug-related toxicities on the estimation of the maximum tolerated dose in phase I trials. Clinical Cancer Research 2012;18(19):5179-87.Grisham RN, Iyer G, Garg K, Delair D, Hyman DM, Zhou Q, Iasonos A, Berger MF, Dao F, Spriggs DR, Levine DA, Aghajanian C, Solit DB. BRAF Mutation is associated with early stage disease and improved outcome in patients with low-grade serous ovarian cancer. Cancer. 2013;119(3):548-54.Balar AV, Apolo A, Ostrovnaya I, Mironov S, Iasonos A, Trout A, Regazzi AM, Garcia-Grossman IR, Gallagher DJ, Milowsky MI, Bajorin DF. Phase II study of gemcitabine, carboplatin, and bevacizumab in patients with advanced unresectable or metastatic urothelial cancer. J Clin Oncol. 2013 Feb 20;31(6):724-30.Apolo AB, Ostrovnaya I, Halabi S, Iasonos A, Philips GK, Rosenberg JE, Riches J, Small EJ, Milowsky MI, Bajorin DF. Prognostic model for predicting survival of patients with metastatic urothelial cancer treated with cisplatin-based chemotherapy. J Natl Cancer Inst. 2013 Apr 3;105(7):499-503. PMCID: PMC3691944.Iasonos A, Keung EZ, Zivanovic O, Mancari R, Peiretti M, Nucci M, George S, Colombo N, Carinelli S, Hensley ML, Raut CP. External validation of a prognostic nomogram for overall survival in women with uterine leiomyosarcoma. Cancer. 2013 May 15;119(10):1816-22. PubMed PMID: 23456762; PubMed Central PMCID: PMC4044863.Makker V, Hensley ML, Zhou Q, Iasonos A, Aghajanian CA. Treatment of advanced or recurrent endometrial carcinoma with doxorubicin in patients progressing after paclitaxel/carboplatin: Memorial Sloan-Kettering Cancer Center experience from 1995 to 2009. Int J Gynecol Cancer. 2013 Jun;23(5):929-34. PubMed PMID: 23598889; PubMed Central PMCID: PMC3694716.Barlin JN, Zhou Q, St Clair CM, Iasonos A, Soslow RA, Alektiar KM, Hensley ML, Leitao MM Jr, Barakat RR, Abu-Rustum NR. Classification and regression tree (CART) analysis of endometrial carcinoma: Seeing the forest for the trees. Gynecol Oncol. 2013 Sep;130(3):452-6. PMCID: PMC3748179.Makker V, Kravetz SJ, Gallagher J, Orodel OP, Zhou Q, Iasonos A, DeLair D, Aghajanian C, Hensley ML. Treatment outcomes in completely resected stage I to stage IV uterine carcinosarcoma with rhabdomyosarcoma differentiation. Int J Gynecol Cancer. 2013 Nov;23(9):1635-41. PubMed PMID: 24172099.Barlin JN, Soslow RA, Lutz M, Zhou QC, St Clair CM, Leitao MM Jr, Iasonos A, Hensley ML, Barakat RR, Matias-Guiu X, Abu-Rustum NR. Redefining stage I endometrial cancer: incorporating histology, a binary grading system, myometrial invasion, and lymph node assessment. Int J Gynecol Cancer. 2013 Nov;23(9):1620-8. PubMed PMID: 24126219.Barlin JN, Soslow RA, Lutz M, Zhou QC, St Clair CM, Leitao MM Jr, Iasonos A, Hensley ML, Barakat RR, Matias-Guiu X, Abu-Rustum NR. Redefining stage I endometrial cancer: incorporating histology, a binary grading system, myometrial invasion, and lymph node assessment. Int J Gynecol Cancer. 2013 Nov;23(9):1620-8. PubMed PMID: 24126219.Iasonos A, O'Quigley J. Design considerations for dose-expansion cohorts in phase I trials. J Clin Oncol. 2013 Nov 1;31(31):4014-21. PubMed PMID: 24101039.Hyman DM, Eaton AA, Gounder MM, Smith GL, Pamer EG, Hensley ML, Spriggs DR, Ivy P, Iasonos A. Nomogram to predict cycle-one serious drug-related toxicity in phase I oncology trials. J Clin Oncol. 2014 Feb 20;32(6):519-26. PubMed PMID: 24419130; PMCID: PMC3918535.O'Quigley J, Iasonos A. Bridging Solutions in Dose Finding Problems. Stat Biopharm Res. 2014 May 1;6(2):185-197. PubMed PMID: 25071878; PubMed Central PMCID: PMC4111208.Grisham RN, Iyer G, Sala E, Zhou Q, Iasonos A, DeLair D, Hyman DM, Aghajanian C. Bevacizumab shows activity in patients with low-grade serous ovarian and primary peritoneal cancer. Int J Gynecol Cancer. 2014 Jul;24(6):1010-4. PubMed PMID: 24978709.Suidan RS, Ramirez PT, Sarasohn DM, Teitcher JB, Mironov S, Iyer RB, Zhou Q, Iasonos A, Paul H, Hosaka M, Aghajanian CA, Leitao MM Jr, Gardner GJ, Abu-Rustum NR, Sonoda Y, Levine DA, Hricak H, Chi DS. A multicenter prospective trial evaluating the ability of preoperative computed tomography scan and serum CA-125 to predict suboptimal cytoreduction at primary debulking surgery for advanced ovarian, fallopian tube, and peritoneal cancer. Gynecol Oncol. 2014 Sep;134(3):455-61. PubMed PMID: 25019568.Hyman DM, Eaton AA, Gounder MM, Ivy SP, Iasonos A, Spriggs DR. Reply to M. Voskoboynik et al. J Clin Oncol. 2014 Oct 1;32(28):3199-200. PMID: 25071117.Meisel JL, Hyman DM, Garg K, Zhou Q, Dao F, Bisogna M, Gao J, Schultz ND, Grisham RN, Phillips M, Iasonos A, Kauff ND, Levine DA, Soslow RA, Spriggs DR. The performance of BRCA1immunohistochemistry for detecting germline, somatic, and epigenetic BRCA1 loss in high-grade serous ovarian cancer. Ann Oncol. 2014 Dec;25(12):2372-8.. PubMed PMID: 25281711.Meisel J, Hyman D, Jotwani A, Zhou Q, Abu-Rustum NR, Iasonos A, Pike MC, Aghajanian C. The Role of Systemic Chemotherapy in the Management of Granulosa Cell Tumors. Gyn Oncology. In press 2015.Hyman DM, Snyder AE, Carvajal RD, Gerecitano JF, Voss MH, Ho AL, Konner J, Winkelmann JL, Stasi MA, Monson KR, Iasonos A, Spriggs DR, Bialer P, Lacouture ME, Teitcher JB, Katabi N, Fury MG. Parallel phase Ib studies of two schedules of buparlisib (BKM120) plus carboplatin and paclitaxel (q21 days or q28 days) for patients with advanced solid tumors. Cancer Chemother Pharmacol. 2015 Apr;75(4):747-55. Suidan RS, Zhou Q, Iasonos A, O'Cearbhaill RE, Chi DS, Long Roche KC, Tanner EJ, Denesopolis J, Barakat RR, Zivanovic O. Prognostic significance of the number of postoperative intraperitoneal chemotherapy cycles for patients with advanced epithelial ovarian cancer. Int J Gynecol Cancer. 2015 May;25(4):599-606. Korc-Grodzicki B, Sun SW, Zhou Q, Iasonos A, Lu B, Root JC, Downey RJ, Tew WP. Geriatric Assessment as a Predictor of Delirium and Other Outcomes in Elderly Patients With Cancer. Ann Surg. 2015 Jun;261(6):1085-90. PubMed PMID: 24887981.Iasonos A., Gonen M., Bosl G. Scientific review of Phase I protocols with novel dose escalation designs: how much information is needed? Journal of Clinical Oncology. 2015 Jul 1;33(19):2221-5. Hyman DM, Eaton AA, Gounder MM, Pamer EG, Pettiford J, Carvajal RD, Ivy SP, Iasonos A, Spriggs DR.. Predictors of Early Treatment Discontinuation in Patients Enrolled on Phase I Oncology Trials. Oncotarget. 2015 Aug 7;6(22):19316-27.Iasonos A, O'Quigley J. Clinical trials: Early phase clinical trials-are dose expansion cohorts needed? Nat Rev Clin Oncol. 2015 Nov;12(11):626-8.Satagopan J, Iasonos A, Zhou Q. Prognostic and predictive values of statistical interactions in the era of personalized medicine. Genet Epidemiol. 2015 Nov;39(7):509-17. Shu CA, Zhou Q, Jotwani AR, Iasonos A, Leitao MM Jr, Konner JA, Aghajanian CA. Ovarian clear cell carcinoma, outcomes by stage: The MSK experience. Gynecol Oncol. 2015 Nov;139(2):236-41.Schiavone MB, Zivanovic O, Zhou Q, Leitao MM Jr, Levine DA, Soslow RA, Alektiar KM, Makker V, Iasonos A, Abu-Rustum NR. Survival of Patients with Uterine Carcinosarcoma Undergoing Sentinel Lymph Node Mapping. Ann Surg Oncol. 2016 Jan;23(1):196-202.Iasonos A and O’Quigley J. Dose expansion cohorts in Phase I trials. Stat Biopharm Res. 2016;8(2):161-170.Eaton A, Iasonos A, Gounder, et al. Toxicity Attribution in Phase I Trials: Evaluating the Effect of Dose on the Frequency of Related and Unrelated Toxicities. Clin Cancer Res. 2016 Feb 1;22(3):553-9.Bell-McGuinn KM, Konner JA, Tew WP, Hensley ML, Iasonos A, Charpentier E, Mironov S, Sabbatini P, Aghajanian C. A Phase 2, Single Arm Study of Iniparib in Patients With BRCA1 or BRCA2 Associated Advanced Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer. Int J Gynecol Cancer. 2016 Feb;26(2):255-60.Mueller JJ, Zhou QC, Iasonos A, O'Cearbhaill RE, Alvi FA, El Haraki A, Eriksson AG, Gardner GJ, Sonoda Y, Levine DA, Aghajanian C, Chi DS, Abu-Rustum NR, Zivanovic O. Neoadjuvant chemotherapy and primary debulking surgery utilization for advanced-stage ovarian cancer at a comprehensive cancer center. Gynecol Oncol. 2016 Mar;140(3):436-42.Liang LW, Perez AR, Cangemi NA, Zhou Q, Iasonos A, Abu-Rustum N, Alektiar KM, Makker V. An Assessment of Prognostic Factors, Adjuvant Treatment, and Outcomes of Stage IA Polyp-Limited Versus Endometrium-Limited Type II Endometrial Carcinoma. Int J Gynecol Cancer. 2016 Mar;26(3):497-504.Hyman DM, Solit DB, Iasonos A. Reply to M.P. Decatris et al. J Clin Oncol. 2016 Mar 10;34(8):887.Hyman DM, Eaton A, Ivy SP, Spriggs DR, Iasonos A. Measuring Toxicity in Phase I Clinical Trials-Letter. Clin Cancer Res. 2016 Apr 1;22(7):1828.Drilon A, Eaton AA, Schindler K, Gounder MM, Spriggs DR, Harris P, Ivy SP, Iasonos A, Lacouture ME, Hyman DM. Beyond the dose-limiting toxicity period: Dermatologic adverse events of patients on phase 1 trials of the Cancer Therapeutics Evaluation Program. Cancer. 2016 Apr 15;122(8):1228-37.O'Cearbhaill RE, Ragupathi G, Zhu J, Wan Q, Mironov S, Yang G, Spassova MK, Iasonos A, Kravetz S, Ouerfelli O, Spriggs DR, Danishefsky SJ, Sabbatini PJ. A Phase I Study of Unimolecular Pentavalent (Globo-H-GM2-sTn-TF-Tn) Immunization of Patients with Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer in First Remission. Cancers (Basel). 2016 Apr 22;8(4).Iasonos A, Chapman PB, Satagopan JM. Quantifying Treatment Benefit in Molecular Subgroups to Assess a Predictive Biomarker. Clin Cancer Res. 2016 May 1;22(9):2114-20.Iasonos A, O'Quigley J. Integrating the escalation and dose expansion studies into a unified Phase I clinical trial. Contemp Clin Trials. 2016 Sep;50:124-34.Iasonos A, Wages NA, Conaway MR, Cheung K, Yuan Y, O'Quigley J. Dimension of model parameter space and operating characteristics in adaptive dose-finding studies. Stat Med. 2016 Sep 20;35(21):3760-75.Mueller JJ, Kelly A, Zhou Q, Iasonos A, Long Roche K, Sonoda Y, O'Cearbhaill RE, Zivanovic O, Chi DS, Gardner GJ. Intraperitoneal chemotherapy after interval debulking surgery for advanced-stage ovarian cancer: Feasibility and outcomes at a comprehensive cancer center. Gynecol Oncol. 2016 Dec;143(3):496-503. doi: 10.1016/j.ygyno.2016.09.014. Epub 2016 Sep 28. PubMed PMID: 27692668; PubMed Central PMCID: PMC5624326Cunanan KM, Iasonos A, Shen R, Begg CB, G?nen M. An efficient basket trialdesign. Stat Med. 2017 May 10;36(10):1568-1579. doi: 10.1002/sim.7227. Epub 2017 Jan 18. PubMed PMID: 28098411; PubMed Central PMCID: PMC5380524.Iasonos A and O’Quigley J. Sequential Monitoring of Phase I Dose expansion cohorts. Stat Med. 2017 Jan 30;36(2):204-214 Suidan RS, Ramirez PT, Sarasohn DM, Teitcher JB, Iyer RB, Zhou Q, Iasonos A, Denesopolis J, Zivanovic O, Long Roche KC, Sonoda Y, Coleman RL, Abu-Rustum NR, Hricak H, Chi DS. A multicenter assessment of the ability of preoperative computed tomography scan and CA-125 to predict gross residual disease at primary debulking for advanced epithelial ovarian cancer. Gynecol Oncol. 2017 Apr;145(1):27-31. doi: 10.1016/j.ygyno.2017.02.020. Epub 2017 Feb 14. PubMed PMID: 28209497; PubMed Central PMCID: PMC5387995.Satagopan JM, Iasonos A. Measuring differential treatment benefit across marker specific subgroups: The choice of outcome scale. Contemp Clin Trials. 2017 Dec;63:40-50. doi: 10.1016/t.2017.02.007. Epub 2017 Feb 22. PubMed PMID: 28254404; PubMed Central PMCID: PMC5568905.Schiavone MB, Scelzo C, Straight C, Zhou Q, Alektiar KM, Makker V, Soslow RA, Iasonos A, Leitao MM, Abu-Rustum NR. Survival of Patients with Serous Uterine Carcinoma Undergoing Sentinel Lymph Node Mapping. Ann Surg Oncol. 2017 Jul;24(7):1965-1971. doi: 10.1245/s10434-017-5816-4. Epub 2017 Mar 3. PubMed PMID: 28258415; PubMed Central PMCID: PMC6092025.Smyth LM, Monson KR, Jhaveri K, Drilon A, Li BT, Abida W, Iyer G, Gerecitano JF, Gounder M, Harding JJ, Voss MH, Makker V, Ho AL, Razavi P, Iasonos A, Bialer P, Lacouture ME, Teitcher JB, Erinjeri JP, Katabi N, Fury MG, Hyman DM. A phase 1b dose expansion study of the pan-class I PI3K inhibitor buparlisib (BKM120) plus carboplatin and paclitaxel in PTEN deficient tumors and with dose intensified carboplatin and paclitaxel. Invest New Drugs. 2017 Dec;35(6):742-750. doi: 10.1007/s10637-017-0445-0. Epub 2017 Mar 9. PubMed PMID: 28281183; PubMed Central PMCID: PMC5591764.Cowan RA, Eriksson AGZ, Jaber SM, Zhou Q, Iasonos A, Zivanovic O, Leitao MM Jr, Abu-Rustum NR, Chi DS, Gardner GJ. A comparative analysis of prediction models for complete gross resection in secondary cytoreductive surgery for ovarian cancer. Gynecol Oncol. 2017 May;145(2):230-235. doi: 10.1016/j.ygyno.2017.02.010. Epub 2017 Mar 9. PubMed PMID: 28285846. Joffe E, Iasonos A, Younes A. Clinical Trials in the Genomic Era. J Clin Oncol. 2017 Mar 20;35(9):1011-1017. doi: 10.1200/JCO.2016.70.8891. Epub 2017 Feb 13. Review. PubMed PMID: 28297622; PubMed Central PMCID: PMC5652384.Satagopan JM, Iasonos A, Kanik JG. A reconstructed melanoma data set for evaluating differential treatment benefit according to biomarker subgroups. Data Brief. 2017 May 5;12:667-675. doi: 10.1016/j.dib.2017.05.005. eCollection 2017 Jun. PubMed PMID: 28560273; PubMed Central PMCID: PMC5435579.Schiavone MB, Moukarzel L, Leong K, Zhou QC, Afonso AM, Iasonos A, Roche KL, Leitao MM Jr, Chi DS, Abu-Rustum NR, Zivanovic O. Surgical site infection reduction bundle in patients with gynecologic cancer undergoing colon surgery. Gynecol Oncol. 2017 Oct;147(1):115-119. doi: 10.1016/j.ygyno.2017.07.010. Epub 2017 Jul 19. PubMed PMID: 28734498; PubMed Central PMCID: PMC5605426.Chapman PB, Liu NJ, Zhou Q, Iasonos A, Hanley S, Bosl GJ, Spriggs DR. Time to publication of oncology trials and why some trials are never published. PLoS One. 2017 Sep 21;12(9):e0184025. doi: 10.1371/journal.pone.0184025. eCollection 2017. PubMed PMID: 28934243; PubMed Central PMCID: PMC5608207.Iasonos A, O'Quigley J. Phase I Designs that Allow for Uncertainty in the Attribution of Adverse Events. J R Stat Soc Ser C Appl Stat. 2017 Nov;66(5):1015-1030. doi: 10.1111/rssc.12195. Epub 2016 Nov 7. PubMed PMID: 29085158; PubMed Central PMCID: PMC5659366.Cunanan KM,?Iasonos A, Shen R, Hyman DM, Riely GJ, G?nen M, Begg CB. Specifying the True- and False-Positive Rates in Basket Trials. JCO Precis Oncol. 2017 Nov 3;1:PO.17.00181. doi: 10.1200/PO.17.00181. PMCID:?PMC7446381Aloisi A, Sonoda Y, Gardner GJ, Park KJ, Elliott SL, Zhou QC, Iasonos A, Abu-Rustum NR. Prospective Comparative Study of Laparoscopic Narrow Band Imaging (NBI) Versus Standard Imaging in Gynecologic Oncology. Ann Surg Oncol. 2018 Apr;25(4):984-990. doi: 10.1245/s10434-017-6314-4. Epub 2018 Jan 16. PubMed PMID: 29340992; PubMed Central PMCID: PMC6091884.Stathis A, Iasonos A, Seymour JF, Thieblemont C, Ribrag V, Zucca E, Younes A. Report of the 14th International Conference on Malignant Lymphoma (ICML) Closed Workshop on Future Design of Clinical Trials in Lymphomas. Clin Cancer Res. 2018 Jul 1;24(13):2993-2998. doi: 10.1158/1078-R-17-3021. Epub 2018 Mar 13. PubMed PMID: 29535129.Mueller JJ, Lajer H, Mosgaard BJ, Bach Hamba S, Morice P, Gouy S, Hussein Y, Soslow RA, Schlappe BA, Zhou QC, Iasonos A, H?gdall C, Leary A, O'Cearbhaill RE, Abu-Rustum NR. International Study of Primary Mucinous Ovarian Carcinomas Managed at Tertiary Medical Centers. Int J Gynecol Cancer. 2018 Jun;28(5):915-924. doi: 10.1097/IGC.0000000000001263. PubMed PMID: 29561302; PubMed Central PMCID: PMC5962416.Cowan RA, Tseng J, Ali N, Dearie H, Murthy V, Gennarelli RL, Iasonos A, Abu-Rustum NR, Chi DS, Long Roche KC, Brown CL. Exploring the impact of income and race on survival for women with advanced ovarian cancer undergoing primary debulking surgery at a high-volume center. Gynecol Oncol. 2018 Apr;149(1):43-48. doi: 10.1016/j.ygyno.2017.11.012. PubMed PMID: 29605049.Oseledchyk A, Gennarelli RL, Leitao MM Jr, Aghajanian CA, Iasonos A, Zivanovic O, Zamarin D. Adjuvant chemotherapy in patients with operable granulosa cell tumors of the ovary: a surveillance, epidemiology, and end results cohort study. Cancer Med. 2018 Jun;7(6):2280-2287. doi: 10.1002/cam4.1447. Epub 2018 Apr 17. PubMed PMID: 29667339; PubMed Central PMCID: PMC6010870.LaVigne K, Hyman DM, Zhou QC, Iasonos A, Tew WP, Aghajanian C, Makker V, Hensley ML, Konner J, Grisham RN, Cangemi N, Soldan K, Spriggs DR, Sabbatini PJ, O?Cearbhaill RE. A Randomized Trial of Prophylactic Extended Carboplatin Infusion to Reduce Hypersensitivity Reactions in Recurrent Ovarian Cancer. Int J Gynecol Cancer. 2018 Jul;28(6):1176-1182. doi: 10.1097/IGC.0000000000001280. PubMed PMID: 29757876; PubMed Central PMCID: PMC6033627.Tseng JH, Cowan RA, Zhou Q, Iasonos A, Byrne M, Polcino T, Polen-De C, Gardner GJ, Sonoda Y, Zivanovic O, Abu-Rustum NR, Long Roche K, Chi DS. Continuous improvement in primary Debulking surgery for advanced ovarian cancer: Do increased complete gross resection rates independently lead to increased progression-free and overall survival? Gynecol Oncol. 2018 Oct;151(1):24-31. doi: 10.1016/j.ygyno.2018.08.014. Epub 2018 Aug 17. PubMed PMID: 30126704.Tseng JH, Cowan RA, Afonso AM, Zhou Q, Iasonos A, Ali N, Thompson E, Sonoda Y, O'Cearbhaill RE, Chi DS, Abu-Rustum NR, Long Roche K. Perioperative epidural use and survival outcomes in patients undergoing primary debulking surgery for advanced ovarian cancer. Gynecol Oncol. 2018 Sep 2. pii: S0090-8258(18)31154-5. doi: 10.1016/j.ygyno.2018.08.024. [Epub ahead of print] PubMed PMID: 30185381 Boland JL, Zhou Q, Martin M, Callahan MK, Konner J, O'Cearbhaill RE, Friedman CF, Tew W, Makker V, Grisham RN, Hensley ML, Zecca N,?Iasonos AE, Snyder A, Hyman DM, Sabbatini P, Aghajanian C, Cadoo KA, Zamarin D. Early disease progression and treatment discontinuation in patients with advanced ovarian cancer receiving immune checkpoint blockade. Gynecol Oncol.?2019 Feb;152(2):251-258. doi: 10.1016/j.ygyno.2018.11.025.?Epub 2018 Nov 22. PMCID:?PMC6613945Cunanan KM,?Iasonos A, Shen R, G?nen M. Variance prior specification for a basket trial design using Bayesian hierarchical modeling. Clin Trials. 2019 Apr;16(2):142-153. doi: 10.1177/1740774518812779. Epub 2018 Dec 7. PMCID:?PMC6822679Feit NZ, Goldman DA, Smith E, Deighan J,?Iasonos A, Zivanovic O, Hyman DM. Use, Safety, and Efficacy of Single-Patient Use of the US Food and Drug Administration Expanded Access Program. JAMA Oncol. 2019 Apr 1;5(4):570-572. doi: 10.1001/jamaoncol.2018.7002. PMCID:?PMC6459119Diamond EL, Durham BH, Ulaner GA, Drill E, Buthorn J, Ki M, Bitner L, Cho H, Young RJ, Francis JH, Rampal R, Lacouture M, Brody LA, Ozkaya N, Dogan A, Rosen N,?Iasonos A, Abdel-Wahab O, Hyman DM. Efficacy of MEK inhibition in patients with histiocytic neoplasms. Nature. 2019 Mar;567(7749):521-524. doi: 10.1038/s41586-019-1012-y. Epub 2019 Mar 13. PMCID:?PMC6438729Schlappe BA, Zhou QC, O'Cearbhaill R,?Iasonos A, Soslow RA, Abu-Rustum NR, Mueller JJ. A descriptive report of outcomes of primary mucinous ovarian cancer patients receiving either an adjuvant gynecologic or gastrointestinal chemotherapy regimen. Int J Gynecol Cancer. 2019 May 15:ijgc-2018-000150. doi: 10.1136/ijgc-2018-000150. PMCID:?PMC7385730Liu YL, Zhou Q,?Iasonos A, Emengo VN, Friedman C, Konner JA, O'Cearbhaill RE, Aghajanian C, Zamarin D. Subsequent therapies and survival after immunotherapy in recurrent ovarian cancer. Gynecol Oncol. 2019 Oct;155(1):51-57. doi: 10.1016/j.ygyno.2019.08.006. Epub 2019 Aug 14. PMCID:?PMC6788969Wages NA,?Iasonos A, O'Quigley J, Conaway MR. Coherence principles in interval-based dose finding. Pharm Stat. 2020 Mar;19(2):137-144. doi: 10.1002/pst.1974. Epub 2019 Nov 6. PMCID:?PMC7065921Leitao MM Jr, Zhou QC, Gomez-Hidalgo NR,?Iasonos A, Baser R, Mezzancello M, Chang K, Ward J, Chi DS, Long Roche K, Sonoda Y, Brown CL, Mueller JJ, Gardner GJ, Jewell EL, Broach V, Zivanovic O, Dowdy SC, Mariani A, Abu-Rustum NR. Patient-reported outcomes after surgery for endometrial carcinoma: Prevalence of lower-extremity lymphedema after sentinel lymph node mapping versus lymphadenectomy. Gynecol Oncol. 2020 Jan;156(1):147-153. doi: 10.1016/j.ygyno.2019.11.003 PMCID:?PMC6980687Liu YL, Filippova OT, Zhou Q,?Iasonos A, Chi DS, Zivanovic O, Sonoda Y, Gardner GJ, Broach VA, O'Cearbhaill RE, Konner JA, Aghajanian C, Long Roche K, Tew WP. Characteristics and survival of ovarian cancer patients treated with neoadjuvant chemotherapy but not undergoing interval debulking surgery. J Gynecol Oncol. 2020 Jan;31(1):e17. doi: 10.3802/jgo.2020.31.e17. PMCID:?PMC6918896Rosen EY, Goldman DA, Hechtman JF, Benayed R, Schram AM, Cocco E, Shifman S, Gong Y, Kundra R, Solomon JP, Bardelli A, Scaltriti M, Drilon A,?Iasonos A, Taylor BS, Hyman DM. TRK Fusions Are Enriched in Cancers with Uncommon Histologies and the Absence of Canonical Driver Mutations. Clin Cancer Res. 2020 Apr 1;26(7):1624-1632. doi: 10.1158/1078-R-19-3165. Epub 2019 Dec 23. PMCID:?PMC7124988Hutchinson N, Vinarov E,?Iasonos A, Kimmelman J. Ethical and Policy Issues for Seamless Phase I Oncology Trials. J Clin Oncol. 2020 Mar 1;38(7):669-673. doi: 10.1200/JCO.19.02456. Epub 2019 Dec 26.Rubinstein MM, Hyman DM, Caird I, Won H, Soldan K, Seier K,?Iasonos A, Tew WP, O'Cearbhaill RE, Grisham RN, Hensley ML, Troso-Sandoval T, Sabbatini P, Guillen J, Selcuklu SD, Zimel C, Torrisi J, Aghajanian C, Makker V. Phase 2 study of LY3023414 in patients with advanced endometrial cancer harboring activating mutations in the PI3K pathway. Cancer. 2020 Mar 15;126(6):1274-1282. doi: 10.1002/cncr.32677. PMCID:?PMC7444087Smyth LM, Zhou Q, Nguyen B, Yu C, Lepisto EM, Arnedos M, Hasset MJ, Lenoue-Newton ML, Blauvelt N, Dogan S, Micheel CM, Wathoo C, Horlings H, Hudecek J, Gross BE, Kundra R, Sweeney SM, Gao J, Schultz N, Zarski A, Gardos SM, Lee J, Sheffler-Collins S, Park BH, Sawyers CL, André F, Levy M, Meric-Bernstam F, Bedard PL,?Iasonos A, Schrag D, Hyman DM; AACR Project GENIE Consortium. Characteristics and Outcome of?AKT1?E17K-Mutant Breast Cancer Defined through AACR Project GENIE, a Clinicogenomic Registry. Cancer Discov. 2020 Apr;10(4):526-535. doi: 10.1158/2159-8290.CD-19-1209. Epub 2020 Jan 10. PMCID:?PMC7125034Mueller JJ, Dauer LT, Murali R,?Iasonos A, Pandit-Taskar N, Abu-Rustum NR, Grimm J. Positron Lymphography via Intracervical?18F-FDG Injection for Presurgical Lymphatic Mapping in Cervical and Endometrial Malignancies. J Nucl Med. 2020 Aug;61(8):1123-1130. doi: 10.2967/jnumed.119.230714. Epub 2020 Jan 10. PMCID:?PMC7413230?Cadoo KA, Grisham RN, O'Cearbhaill RE, Boucicaut NN, Henson M,?Iasonos A, Zhou Q, Sarasohn DM, Gallagher J, Kravetz S, Zamarin D, Makker V, Sabbatini PJ, Tew WP, Aghajanian C, Konner JA. A phase 1 dose-escalation study of intraperitoneal cisplatin, intravenous/intraperitoneal paclitaxel, bevacizumab, and olaparib for newly diagnosed ovarian cancer. Gynecol Oncol. 2020 Apr;157(1):214-221.?PMCID:?PMC7127949?Moukarzel LA, Byrne ME, Leiva S, Wu M, Zhou QC,?Iasonos A, Abu-Rustum NR, Sonoda Y, Gardner G, Leitao MM Jr, Broach VA, Chi DS, Long Roche K, Zivanovic O. The impact of near-infrared angiography and proctoscopy after rectosigmoid resection and anastomosis performed during surgeries for gynecologic malignancies. Gynecol Oncol. 2020 Aug;158(2):397-401. doi: 10.1016/j.ygyno.2020.05.022. Epub 2020 May 24. PMCID:?PMC7693678?Pedra Nobre S, Mazina V,?Iasonos A, Zhou QC, Sonoda Y, Gardner G, Long-Roche K, Leitao MM, Abu-Rustum NR, Mueller JJ. Surveillance patterns of cervical cancer patients treated with conization alone. Int J Gynecol Cancer. 2020 Aug;30(8):1129-1135. doi: 10.1136/ijgc-2020-001338.?Zamarin D, Walderich S, Holland A, Zhou Q,?Iasonos AE, Torrisi JM, Merghoub T, Chesebrough LF, Mcdonnell AS, Gallagher JM, Li Y, Hollmann TJ, Grisham RN, Erskine CL, Block MS, Knutson KL, O'Cearbhaill RE, Aghajanian C, Konner JA. Safety, immunogenicity, and clinical efficacy of durvalumab in combination with folate receptor alpha vaccine TPIV200 in patients with advanced ovarian cancer: a phase II trial. J Immunother Cancer. 2020 Jun;8(1):e000829. doi: 10.1136/jitc-2020-000829. PMCID:?PMC7279674Boland JL, Zhou Q,?Iasonos AE, O'Cearbhaill RE, Konner J, Callahan M, Friedman C, Aghajanian C, Sabbatini P, Zamarin D, Cadoo KA. Utility of serum CA-125 monitoring in patients with ovarian cancer undergoing immune checkpoint inhibitor therapy Gynecol Oncol. 2020 Aug;158(2):303-308. doi: 10.1016/j.ygyno.2020.04.710. Epub 2020 Jun 2. PMCID:?PMC7423717?Liu YL, Zhou QC,?Iasonos A, Filippova OT, Chi DS, Zivanovic O, Sonoda Y, Gardner G, Broach V, OCearbhaill R, Konner JA, Aghajanian CA, Long K, Tew W. Delays from neoadjuvant chemotherapy to interval debulking surgery and survival in ovarian cancer. Int J Gynecol Cancer. 2020 Oct;30(10):1554-1561. DOI:?10.1136/ijgc-2019-000989Filippova OT, Kim SW, Cowan RA, Chi AJ,?Iasonos A, Zhou QC, Broach V, Zivanovic O, Long Roche K, Sonoda Y, Gardner G, Chi DS. Hematologic changes after splenectomy for ovarian cancer debulking surgery, and association with infection and venous thromboembolism. Int J Gynecol Cancer. 2020 Aug;30(8):1183-1188. doi: 10.1136/ijgc-2020-001368. Epub 2020 Jul 13.Boerner T, Filippova OT, Chi AJ,?Iasonos A, Zhou QC, Long Roche K, Zivanovic O, Park BJ, Huang J, Jones DR, Abu-Rustum NR, Gardner G, Sonoda Y, Chi DS. Video-assisted thoracic surgery in the primary management of advanced ovarian carcinoma with moderate to large pleural effusions: A Memorial Sloan Kettering Cancer Center Team Ovary Study. Gynecol Oncol. 2020 Oct;159(1):66-71. doi: 10.1016/j.ygyno.2020.07.101. Epub 2020 Aug 10. ? PMCID:?PMC7541719?Iasonos A. Finding Optimism in Clinical Trials: A Numbers Perspective. Oncologist. 2020 Sep 1. doi: 10.1634/theoncologist.2020-0543Liu YL, Selenica P, Zhou Q,?Iasonos A, Callahan M, Feit NZ, Boland J, Vazquez-Garcia I, Mandelker D, Zehir A, Burger RA, Powell DJ Jr, Friedman C, Cadoo K, Grisham R, Konner JA, O'Cearbhaill RE, Aghajanian C, Reis-Filho JS, Weigelt B, Zamarin D. BRCA?Mutations, Homologous DNA Repair Deficiency, Tumor Mutational Burden, and Response to Immune Checkpoint Inhibition in Recurrent Ovarian Cancer. JCO Precis Oncol. 2020 Jun 16;4:PO.20.00069. doi: 10.1200/PO.20.00069. eCollection 2020. PMCID:?PMC7446408Friedman CF, Snyder Charen A, Zhou Q, Carducci MA, Buckley De Meritens A, Corr BR, Fu S, Hollmann TJ,?Iasonos A, Konner JA, Konstantinopoulos PA, Modesitt SC, Sharon E, Aghajanian C, Zamarin D. Phase II study of atezolizumab in combination with bevacizumab in patients with advanced cervical cancer. J Immunother Cancer. 2020 Oct;8(2):e001126. doi: 10.1136/jitc-2020-001126. PMCID:?PMC7534695Liu YL, Zhou QC,?Iasonos A, Chi DS, Zivanovic O, Sonoda Y, Gardner G, Broach V, O'Cearbhaill R, Konner JA, Grisham R, Aghajanian CA, Abu-Rustum NR, Tew W, Long Roche K. Pre-operative neoadjuvant chemotherapy cycles and survival in newly diagnosed ovarian cancer: what is the optimal number? A Memorial Sloan Kettering Cancer Center Team Ovary study. Int J Gynecol Cancer. 2020 Dec;30(12):1915-1921. doi: 10.1136/ijgc-2020-001641. Epub 2020 Oct 26.Rubinstein MM, Grisham RN, Cadoo K, Kyi C, Tew WP, Friedman CF, O'Cearbhaill RE, Zamarin D, Zhou Q,?Iasonos A, Nikolovski I, Xu H, Soldan KN, Caird I, Martin M, Guillen J, Eid KT, Aghajanian C, Makker V. A phase I open-label study of selinexor with paclitaxel and carboplatin in patients with advanced ovarian or endometrial cancers. Gynecol Oncol. 2021 Jan;160(1):71-76. doi: 10.1016/j.ygyno.2020.10.019. Epub 2020 Nov 1. PMCID:?PMC7779742?Pedra Nobre S, Hensley ML, So M, Zhou QC,?Iasonos A, Leitao MM Jr, Ducie J, Chiang S, Mueller JJ, Abu-Rustum NR, Zivanovic O. The impact of tumor fragmentation in patients with stage I uterine leiomyosarcoma on patterns of recurrence and oncologic outcome. Gynecol Oncol. 2021 Jan;160(1):99-105. doi: 10.1016/j.ygyno.2020.10.020. Epub 2020 Nov 4. PMCID:?PMC7779751Boerner T, Tanner E, Filippova O, Zhou QC,?Iasonos A, Tew WP, O'Cearbhaill RE, Grisham RN, Gardner GJ, Sonoda Y, Abu-Rustum NR, Zivanovic O, Long Roche K, Afonso AM, Fischer M, Chi DS. Survival outcomes of acute normovolemic hemodilution in patients undergoing primary debulking surgery for advanced ovarian cancer: A Memorial Sloan Kettering Cancer Center Team Ovary study. Gynecol Oncol. 2021 Jan;160(1):51-55. doi: 10.1016/j.ygyno.2020.10.042. Epub 2020 Nov 17.Straubhar AM, Wolf JL, Zhou MQC,?Iasonos A, Cham S, Wright JD, Long Roche K, Chi DS, Zivanovic O. Advanced ovarian cancer and cytoreductive surgery: Independent validation of a risk-calculator for perioperative adverse events. Gynecol Oncol. 2020 Nov 30:S0090-8258(20)34132-9. doi: 10.1016/j.ygyno.2020.11.021. Online ahead of print.Oseledchyk A, Gemignani ML, Zhou QC,?Iasonos A, Elahjji R, Adamou Z, Feit N, Goldfarb SB, Long Roche K, Sonoda Y, Goldfrank DJ, Chi DS, Saban SS, Broach V, Abu-Rustum NR, Carter J, Leitao M, Zivanovic O. Surgical ovarian suppression for adjuvant treatment in hormone receptor positive breast cancer in premenopausal patients. Int J Gynecol Cancer. 2020 Dec 3:ijgc-2020-001966. doi: 10.1136/ijgc-2020-001966. Online ahead of print.Boerner T, Walch HS, Nguyen B,?Iasonos A, Zhou QC, Schultz N, Chui MH, Grisham RN, Tew WP, O'Cearbhaill RE, Aghajanian C, Zivanovic O, Abu-Rustum NR, Gardner GJ, Sonoda Y, Chi DS, Long Roche K. Exploring the clinical significance of serous tubal intraepithelial carcinoma associated with advanced high-grade serous ovarian cancer: A Memorial Sloan Kettering Team Ovary Study. Gynecol Oncol. 2020 Dec 29:S0090-8258(20)34225-6. doi: 10.1016/j.ygyno.2020.12.022. Online ahead of print.Reviews or EditorialsIasonos A, O'Quigley J. Adaptive dose-finding studies: a review of model-guided phase I clinical trials. J Clin Oncol. 2014 Aug 10;32(23):2505-11. Epub 2014 Jun 30. PMCID: PMC4121508.Iasonos A, O’Quigley J. Early phase clinical trials- are dose expansion cohorts needed? Nature Reviews Clinical Oncology. 2015 Nov;12(11):626-8. doi: 10.1038/nrclinonc.2015.174. Epub 2015 Oct 6.Schram AM, Iasonos A, Hyman DM. Picking the Right Patient for Human Epidermal Growth Factor Receptor 3-Targeted Therapy in Platinum-Resistant Ovarian Cancer. J Clin Oncol. 2016 Dec 20;34(36):4312-4314.Iasonos A, O'Quigley J. Early phase dose finding methodology. Stat Med. 2017 Jan 30;36(2):201-203. doi: 10.1002/sim.7155. PubMed PMID: 27921353.Cunanan KM, Gonen M, Shen R, Hyman DM, Riely GJ, Begg CB, Iasonos A. Basket Trials in Oncology: A Trade-Off Between Complexity and Efficiency. J Clin Oncol. 2017 Jan 20;35(3):271-273. doi: 10.1200/JCO.2016.69.9751. Epub 2016 Nov 28. PubMed PMID: 27893325; PubMed Central PMCID: PMC5559900.Books1. O’Quigley J, Iasonos A, Bornkamp B. Handbook of methods for designing, monitoring and analyzing dose finding trials. Chapman and Hall/CRC. Taylor and Francis Group. 2017Chapters1. Iasonos A. Statistics for the beginners in gynaecologic oncology. Textbook of Gynaecological Oncology,? ESGO-ENYGO Endorsed. Gunes T?p K?tabevleri, 2009, p. 150.2. O'Quigley J, Iasonos A. Dose finding designs based on the continual reassessment method. Handbook of Statistics in Clinical Oncology ed. by John Crowley and Маrcеl Dеkkеr. 2011; 21-52.Other (media, DVD’s, etc.)Iasonos A. The Efficacy of Bevacizumab Combined with Chemotherapy for Platinum-Resistant Recurrent Ovarian Cancer Patients and Its Effects On Patient-Reported Outcomes. JCO podcast. 2014 May 1;32 (13): 1302-1308.Iasonos A. Disease-Free Survival among Ovarian Cancer Patients: Time in Remission Matters. JCO podcast. 2014 December 20; 32(36): 4102-4112 ................
................

In order to avoid copyright disputes, this page is only a partial summary.

Google Online Preview   Download